HBV
Precision BioSciences Launches First Hepatitis B Gene-Editing Trial
PBGENE-HBV is designed to eliminate covalently closed circular DNA and stop the hepatitis B virus from replicating, using the company's Arcus gene-editing platform.
Precision BioSciences Putting Together IND Data Package for Hepatitis B Gene-Editing Therapy
The firm said it plans to submit an investigational new drug application or a clinical trial application for the gene-editing therapy in 2024.
SCG Cell Therapy to Begin Trials of T-Cell Receptor Therapy for Liver Cancer Patients in Singapore
The firm received IND clearance from regulators in Singapore and China to begin evaluating its therapy SCG101 for HBV-associated hepatocellular carcinoma patients.